论文部分内容阅读
目的探讨人表皮生长因子受体Ⅱ(HER2/neu)与乳腺癌耐受蛋白(BCRP)在乳腺癌组织中的表达及在乳腺癌化疗中的潜在价值。方法采用RT-PCR和免疫组织化学方法分别检测48例乳腺癌组织和相应的癌旁组织的HER2、BCRP的转录和蛋白质水平的表达。结果RT-PCR结果显示,乳腺癌组织中HER2和BCRP阳性率分别是29%(14/48)和33%(16/48),明显高于癌旁组织[4%(2/48)和6%(3/48),P<0.001];免疫组化检测癌组织发现HER2和BCRP的表达率分别为30%(12/40)和33%(11/34),与RT-PCR结果一致,且9例HER2表达阳性的组织中BCRP表达均为阳性,二者的表达高度相关,P<0.001。结论HER2和BCRP在乳腺癌组织比癌旁组织有明显增加的表达率,且两基因的表达相关,提示两基因表达的上调在乳腺癌的发生及恶性表型维持中可能起一定作用。
Objective To investigate the expression of human epidermal growth factor receptor Ⅱ (HER2 / neu) and breast cancer resistance protein (BCRP) in breast cancer and its potential value in chemotherapy of breast cancer. Methods RT-PCR and immunohistochemistry were used to detect the expression of HER2 and BCRP in 48 cases of breast cancer tissues and corresponding paracancerous tissues. Results The positive rates of HER2 and BCRP in breast cancer tissues were 29% (14/48) and 33% (16/48) respectively, which were significantly higher than those in paracancerous tissues [4% (2/48) and 6 % (3/48), P <0.001]. The positive rates of HER2 and BCRP were 30% (12/40) and 33% (11/34) The expression of BCRP in all the 9 HER2 positive tissues was positive, the expression of which was highly correlated, P <0.001. Conclusion The expression of HER2 and BCRP in breast cancer tissues is significantly higher than that in paracancerous tissues, and the expression of both genes is correlated. It suggests that the upregulation of both genes may play a role in the occurrence of breast cancer and the maintenance of malignant phenotype.